The proportion of CDK4/6i reports with PAEs among all CDK4/6i reports also showed an increasing trend, rising from 3.16% (62/1964) in 2015 to 9.55% (1797/18,823) in 2023, with a total proportion of 6.72% (6428/95,591).
← all excerpts
Spectrum of psychiatric adverse reactions to cyclin-dependent kinases 4/6 inhibitors: A pharmacovigilance analysis of the FDA adverse event reporting system.
1
—
—